Mejstríková, E.
Hrusak, O.
Borowitz, M. J.
Whitlock, J. A.
Brethon, B.
Trippett, T. M.
Zugmaier, G.
Gore, L.
von Stackelberg, A.
Locatelli, F.
Article History
Received: 5 September 2017
Revised: 4 October 2017
Accepted: 12 October 2017
First Online: 20 December 2017
Competing interests
: E.M., O.H., and M.J.B. performed MRD assessments as a service to Amgen. M.J.B. reports research grants from Becton Dickinson Biosciences and participated on a speakers bureau for Beckman Coulter. J.A.W. reports research grants/funding for trials from Novartis and Amgen and consulting fees from Jazz Pharmaceuticals, Shire, Amgen, and Gilead. G.Z. is an employee of and owns stock in Amgen. L.G. received consulting fees from Amgen, Novartis, and Celgene; is on the board of directors for Round River Ranch/Serious Fun Network; and owns stock in Amgen, Celgene, Clovis Oncology, and Sanofi PARIS. A.V.S. reports consulting fees from Amgen. The remaining authors (B.B., T.M.T., and F.L.) declare that they have no competing financial interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.